Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Strattera Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 876-A

    Strattera (atomoxetine HCl) Prior Authorization

    Customize your policy alerts

    Sign up for cvs_caremark Policy 876-A alerts

    Get alerted when Policy 876-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization for Strattera and generic atomoxetine HCl in all dosage forms and strengths. Coverage applies to patients being treated for ADHD or ADD when the specified diagnostic documentation, clinical monitoring, and continuation criteria are met.

    Policy Summary
    PayerCVS Caremark
    PolicyStrattera (atomoxetine HCl) Prior Authorization
    Policy CodePolicy 876-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the ADHD or ADD diagnosis and closely monitor the patient for suicidal thinking or behavior, clinical worsening, and unusual behavior changes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ADHD/ADDCovered diagnosis
    2Initial criteria requirements
    3Continuation criteria requirements
    36 monthsApproval duration
    7

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Clinical trials cited

    Coverage Criteria

    Initial therapy

    Covered when all of the following are met.

    Initial ADHD/ADD therapy

    • Diagnosis documentation: The diagnosis has been appropriately documented, such as through a complete clinical assessment using DSM-5, standardized rating scales, interviews, or questionnaires.
    • Safety monitoring: The patient will be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.

    Continuation therapy

    Covered when all of the following are met.

    Continuation ADHD/ADD therapy

    • Clinical response: The patient has achieved or maintained improvement in signs and symptoms of ADHD/ADD from baseline.
    • Annual reassessment: The patient's need for continued therapy has been assessed within the previous year.Within the previous year
    • Safety monitoring: The patient will continue to be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Criteria

    For initial Strattera authorization, the patient must have a documented diagnosis of ADHD or ADD and meet both required criteria: appropriate diagnostic documentation and a plan for close safety monitoring.

    • Diagnosis of ADHD or ADD is appropriately documented.
    • Patient will be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.
    Prior Authorization

    Continuation Authorization Criteria

    Continuation authorization requires documented improvement or maintained improvement in ADHD/ADD signs and symptoms from baseline, assessment of continued treatment need within the previous year, and continued close safety monitoring.

    • Patient has achieved or maintained improvement from baseline.
    • Need for continued therapy was assessed within the previous year.
    • Monitoring will continue for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.

    Clinical Background

    Strattera (atomoxetine) is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD). The policy cites efficacy evidence from seven clinical trials: four 6- to 9-week trials in pediatric patients ages 6 to 18, two 10-week trials in adults, and one pediatric maintenance trial in patients ages 6 to 15.

    Initial Therapy

    Initial therapy

    Initial authorization may be granted when all of the following are met.

    • Diagnosis documentation: The diagnosis has been appropriately documented, such as through a complete clinical assessment using DSM-5, standardized rating scales, interviews, or questionnaires.
    • Safety monitoring: The patient will be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.

    Continuation of Therapy

    Continuation of therapy

    Continuation authorization may be granted when all of the following are met.

    Continuation therapy

    • Response: The patient has achieved or maintained improvement in signs and symptoms of ADHD/ADD from baseline.
    • Reassessment: The patient's need for continued therapy has been assessed within the previous year.Within the previous year
    • Monitoring: The patient will continue to be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.
    Policy Summary
    PayerCVS Caremark
    PolicyStrattera (atomoxetine HCl) Prior Authorization
    Policy CodePolicy 876-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the ADHD or ADD diagnosis and closely monitor the patient for suicidal thinking or behavior, clinical worsening, and unusual behavior changes.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsClinical BackgroundInitial TherapyContinuation of Therapy
    Documentation Required

    Diagnostic Assessment

    Document ADHD or ADD through an appropriate clinical assessment. Acceptable support may include a complete clinical assessment using DSM-5 criteria, standardized rating scales, and interviews or questionnaires.

    • Record the clinical assessment supporting the diagnosis.
    • Include the applicable DSM-5 assessment, standardized rating scales, interviews, or questionnaires.
    Documentation Required

    Continuation Response and Reassessment

    For continuation, document that ADHD/ADD signs and symptoms have improved or remained improved from baseline and that the patient's ongoing need for therapy was reassessed within the previous year.

    • Document response or maintenance of improvement from baseline.
    • Document reassessment of continued treatment need within the last year.
    Documentation Required

    Safety Monitoring Plan

    Establish and document a plan for close clinical monitoring throughout therapy, including monitoring for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.

    • Monitor for suicidal thinking or behavior.
    • Monitor for clinical worsening.
    • Monitor for unusual changes in behavior.
    Denial Risk

    Insufficient Diagnostic Documentation

    Authorization may be denied when ADHD or ADD is not appropriately documented through an adequate clinical assessment and supporting diagnostic records.

    • Ensure the diagnosis is supported by appropriate clinical documentation, such as DSM-5 assessment, standardized rating scales, interviews, or questionnaires.
    Denial Risk

    Required Safety Monitoring Absent

    Authorization may be denied when close safety monitoring is not planned or documented for suicidal thinking or behavior, clinical worsening, and unusual behavioral changes.

    • Document the monitoring plan and its scope before requesting authorization.
    Denial Risk

    Continuation Criteria Not Met

    Continuation authorization may be denied when improvement or maintenance of improvement from baseline is not documented, continued treatment need was not assessed within the previous year, or continuation safety monitoring requirements are not satisfied.

    • Document response or maintained improvement from baseline.
    • Document assessment of continued therapy need within the previous year.
    • Document ongoing monitoring for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior.